Trial Underway Over Cymbalta Withdrawal Symptoms in California Federal Court

The first of several hundred Cymbalta lawsuits pending against Eli Lilly & Co. is going before a jury this week, involving allegations that the drug maker failed to adequately warn about the risk of severe withdrawal symptoms associated with the popular antidepressant.

Trial began on Tuesday in the U.S. District Court for the Central District of California for a case filed by Claudia Herrera, who alleges that she suffered severe withdrawal symptoms when she tried to stop using the drug.

The complaint (PDF) was originally filed in 2013, indicating that side effects of Cymbalta caused Herrera to suffer severe and dangerous withdrawal symptoms after using the medication for more than five years. Herrera indicates that she experienced sharp, painful zaps of electricity shooting through her head. She also indicates that the Cymbalta withdrawal symptoms caused her to experience extreme anxiety and fear, stomach pains, suicidal ideation, uncontrollable muscle spasms, hot flashes, and body shivers.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

Herrera is one of about 250 people pursuing a Cymbalta withdrawal lawsuit against Eli Lilly, according to a report by Reuters.

Cymbalta Withdrawal Side Effects

Cymbalta (duloxetine) was approved by the FDA in 2004, for the treatment of depression. It is part of a family of drugs known as selective serotonin reuptake inhibitors (SSRIs), which have been linked to symptoms of withdrawal since at least 2001.

According to a 2012 report by the Institute for Safe Medication Practices (ISMP), early clinical studies have shown that about half of patients who abruptly discontinued use of Cymbalta suffered withdrawal symptoms.

About 10% of those cases involved severe problems and more than half of the cases involved side effects that lasted longer than a week or two.

Instead of providing clear information about the risk of serious and potentially severe withdrawal symptoms with Cymbalta, plaintiffs in the lawsuits allege that the medication guide and label provided with the drug provided only a very vague warning.

Cymbalta Litigation

The Herrara trial comes as a panel of federal judges are being asked to consolidate all Cymbalta lawsuits pending throughout the federal court system before one judge for coordinated pretrial proceedings.

The U.S. Judicial Panel on Multidistrict Litigation (JPML) previously rejected a similar request in December 2014, indicating at that time that there were too few cases and only a limited number of law firms involved in the lawsuits. Therefore, cases like Herrara’s have been providing individually in different U.S. District Courts nationwide.

In a motion filed last month, a group of plaintiffs asked the U.S. JPML to reconsider the centralization of the Cymbalta litigation, indicating that it is necessary to reduce duplicative discovery into common issues, avoid conflicting pretrial rulings from different judges and to serve the convenience of the parties, witnesses and the courts.

While the outcome of the Herrara case will not be binding on other lawsuits, it will be closely watched as it may help gauge how juries will respond to certain evidence and testimony that is likely to be repeated throughout the litigation. The outcome may also impact potential Cymbalta settlement negotiations to avoid additional trials if Herrara is successful in her claim.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

More Than 9,600 Join Suboxone Lawsuit Over Tooth Decay in MDL Filing
More Than 9,600 Join Suboxone Lawsuit Over Tooth Decay in MDL Filing (Posted today)

A bundled complaint of about 9,600 Suboxone lawsuits were filed in federal court on Friday, ahead of the two-year anniversary of the FDA requiring tooth decay label warnings on the opioid treatment film strips, which is also a deadline for filing a civil complaint in many states.

Lawyers Propose Direct Filing of Toxic Baby Food Lawsuits Over Autism, ADHD in Federal MDL
Lawyers Propose Direct Filing of Toxic Baby Food Lawsuits Over Autism, ADHD in Federal MDL (Posted today)

A federal judge has been asked to allow direct filing of future baby food lawsuits over autism and ADHD side effects with the MDL court, but the parties disagree over whether that order should allow multi-plaintiff complaints.

Social Media Mental Health Warnings Should Be Required To Protect Teens: U.S. Surgeon General
Social Media Mental Health Warnings Should Be Required To Protect Teens: U.S. Surgeon General (Posted 2 days ago)

U.S. Surgeon General says social media platforms like Facebook, Instagram and Tiktok should carry label warnings, alerting parents that youth who use the platforms face an increased risk of mental health side effects.